The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

Syeda Maheen Batool; Anudeep Yekula; Prerna Khanna; Tiffaney Hsia; Austin S Gamblin; Emil Ekanayake; Ana K Escobedo; Dong Gil You; Cesar M Castro; Hyungsoon Im; Tugba Kilic; Michelle Andrea Garlin; Johan Skog; Daniela M Dinulescu; Jonathan Dudley; Nishant Agrawal; Jordan Cheng; Fereidoun Abtin; Denise R Aberle; David Chia; David Elashoff; Tristan Grognan; Kostyantyn Krysan; Scott S Oh; Charles Strom; Michael Tu; Fang Wei; Rena R Xian; Steven J Skates; David Y Zhang; Thi Trinh; Mark Watson; Rebecca Aft; Siddarth Rawal; Ashutosh Agarwal; Susan B Kesmodel; Changhuei Yang; Cheng Shen; Fred H Hochberg; David T W Wong; Abhijit A Patel; Nickolas Papadopoulos; Chetan Bettegowda; Richard J Cote; Sudhir Srivastava; Hakho Lee; Bob S Carter; Leonora Balaj

doi:10.1016/j.xcrm.2023.101198

The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

Cell Rep Med. 2023 Oct 17;4(10):101198. doi: 10.1016/j.xcrm.2023.101198. Epub 2023 Sep 15.

Authors

Syeda Maheen Batool¹, Anudeep Yekula¹, Prerna Khanna¹, Tiffaney Hsia¹, Austin S Gamblin¹, Emil Ekanayake¹, Ana K Escobedo¹, Dong Gil You¹, Cesar M Castro¹, Hyungsoon Im¹, Tugba Kilic¹, Michelle Andrea Garlin¹, Johan Skog², Daniela M Dinulescu³, Jonathan Dudley⁴, Nishant Agrawal⁵, Jordan Cheng⁶, Fereidoun Abtin⁶, Denise R Aberle⁶, David Chia⁶, David Elashoff⁶, Tristan Grognan⁶, Kostyantyn Krysan⁶, Scott S Oh⁶, Charles Strom⁶, Michael Tu⁷, Fang Wei⁶, Rena R Xian⁴, Steven J Skates¹, David Y Zhang⁸, Thi Trinh⁹, Mark Watson¹⁰, Rebecca Aft¹⁰, Siddarth Rawal¹¹, Ashutosh Agarwal¹², Susan B Kesmodel¹², Changhuei Yang¹³, Cheng Shen¹³, Fred H Hochberg¹⁴, David T W Wong⁶, Abhijit A Patel⁹, Nickolas Papadopoulos⁴, Chetan Bettegowda⁴, Richard J Cote¹¹, Sudhir Srivastava¹⁵, Hakho Lee¹, Bob S Carter¹, Leonora Balaj¹⁶

Affiliations

¹ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Exosome Diagnostics Inc., Waltham, MA, USA.
³ Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁵ University of Chicago School of Medicine, Chicago, IL, USA.
⁶ University of California Los Angeles, Los Angeles, CA, USA.
⁷ Liquid Diagnostics LLC., Los Angeles, CA, USA.
⁸ Rice University, Houston, TX, USA.
⁹ Yale University School of Medicine, New Haven, CT, USA.
¹⁰ Washington University School of Medicine, St. Louis, MO, USA.
¹¹ Washington University School of Medicine, St. Louis, MO, USA; Circulogix Inc., St. Louis, MO, USA.
¹² University of Miami, Miami, FL, USA.
¹³ California Institute of Technology, Pasadena, CA, USA.
¹⁴ Scintillon Institute, La Jolla, CA, USA.
¹⁵ Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
¹⁶ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: balaj.leonora@mgh.harvard.edu.

Abstract

The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Biomarkers
Cell-Free Nucleic Acids* / genetics
Extracellular Vesicles*
Humans
Liquid Biopsy
Neoplastic Cells, Circulating* / pathology

Substances

Cell-Free Nucleic Acids
Biomarkers

Abstract

Publication types

MeSH terms

Substances

Grants and funding